- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 20.05. | Pharmala Biotech Holdings Inc: Pharmala signs U.S. ALA-002 licensing term sheet | 3 | Stockwatch | ||
| 20.05. | PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million | 1 | GlobeNewswire (USA) | ||
| 20.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | 652 | GlobeNewswire (Europe) | Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May... ► Artikel lesen | |
| 14.05. | Pharmala Biotech Holdings Inc: Pharmala signs definitive agreement to form SPV Restora | 1 | Stockwatch | ||
| 13.05. | PharmAla forms joint venture to develop novel MDXX molecule | 1 | Investing.com | ||
| 13.05. | PharmAla gründet Joint Venture zur Entwicklung eines neuartigen MDXX-Moleküls | 2 | Investing.com Deutsch | ||
| 13.05. | PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01 | 145 | GlobeNewswire (Europe) | TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) ("PharmAla" or the "Company"), a leader in the research, development, and manufacturing of clinical-grade... ► Artikel lesen | |
| 27.04. | Pharmala Biotech Holdings Inc: Pharmala, Aluvaris sign LOI for special-purpose vehicle | 3 | Stockwatch | ||
| 22.04. | Pharmala Biotech Holdings Inc: Pharmala Biotech loses $337,696 in Q2, grants options | 1 | Stockwatch | ||
| 21.04. | Pharmala Biotech Holdings reports Q2 results | 1 | Seeking Alpha | ||
| 21.04. | Pharmala Biotech Holdings Inc: Pharmala eyes U.S. MDMA access | 2 | Stockwatch | ||
| 20.04. | PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order | 2 | GlobeNewswire (USA) | ||
| 23.03. | Pharmala Biotech Holdings Inc: Pharmala begins second MDMA batch with Cortexa JV | 1 | Stockwatch | ||
| 23.03. | PharmAla Biotech: Cortexa Advances Commercialisation of MDMA Supply in Australia | 210 | GlobeNewswire (Europe) | MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading psychedelic medicines supplier, reaffirms its market leading position in FY2026 for MDMA (3,4-methylenedioxymethamphetamine).... ► Artikel lesen | |
| 03.03. | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA for U.S. study | 4 | Stockwatch | ||
| 03.03. | PharmAla signs MDMA supply deal with Nautilus Sanctuary | 1 | Investing.com | ||
| 27.02. | Pharmala Biotech Holdings Inc: Pharmala signs drug donation deal with Spaulding | 3 | Stockwatch | ||
| 26.02. | PharmAla Biotech: PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia | 1 | GlobeNewswire (USA) | ||
| 24.02. | Pharmala Biotech Holdings Inc: Pharmala signs supply deal with Amsterdam UMC | 2 | Stockwatch | ||
| 23.02. | PharmAla Biotech: PharmAla To Supply Amsterdam UMC with LaNeo MDMA, Including Development of New Single-Capsule Stability Data | 311 | GlobeNewswire (Europe) | TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo MDMA and... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,66 | +0,04 % | Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy | ||
| PRAXIS PRECISION MEDICINES | 349,93 | -0,18 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 32,550 | -0,03 % | Jefferies upgrades Tango Therapeutics stock rating on cancer trial data | ||
| VERA THERAPEUTICS | 43,130 | -0,05 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 109,43 | +0,10 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| ERASCA | 18,290 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,740 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,340 | 0,00 % | Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? | ||
| MINERALYS THERAPEUTICS | 26,880 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 62,41 | 0,00 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| ABSCI | 11,345 | -0,04 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,310 | -0,07 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| RELAY THERAPEUTICS | 19,740 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| BEAM THERAPEUTICS | 34,950 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 50,86 | +0,02 % | Jones Trading raises Enliven Therapeutics price target on CML trials |
PHARMALA BIOTECH HOLDINGS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.